Neil M. Iyengar, MD

Articles

Selecting and Sequencing Therapy for HER2+ Breast Cancer

April 1st 2022

Shared insight on the optimal sequencing of therapeutic agents for patients undergoing treatment for HER2+ metastatic breast cancer.

HER2+ Breast Cancer: Overview of the Treatment Armamentarium

April 1st 2022

Comprehensive insight on therapeutic classes and agents approved in the setting of HER2+ metastatic breast cancer, with a specific focus on how these therapies fit into current treatment strategies.

Dr. Iyengar on Trastuzumab Deruxtecan in HER2-Low Breast Cancer

February 21st 2022

Neil M. Iyengar, MD, discusses the use of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.

Treatment Advances in HR+/HER2- MBC

November 29th 2021

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.

Sequencing Therapy in HR+/HER2- MBC

November 29th 2021

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

PI3K Therapy for HR+/HER2- MBC: Metabolic Syndrome

November 22nd 2021

Strategies to help breast oncologists counsel patients on metabolic conditions when treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitors.

Managing Patients With HR+ MBC on PI3K Therapy

November 22nd 2021

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

PI3K Inhibitors for PIK3CA-Mutated HR+ MBC

November 15th 2021

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

CDK4/6 Treatment Selection for HR+/HER2- MBC

November 8th 2021

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

Comparison of CDK4/6 Therapies for HR+/HER2- MBC

November 8th 2021

Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities

November 1st 2021

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

MONALEESA Data in HR+/HER2- MBC: Sequencing Therapy

October 25th 2021

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.

Ribociclib + ET for HR+/HER2- MBC: QoL and OS Data

October 25th 2021

Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.

Frontline Treatment Approaches for HR+/HER2- MBC

October 18th 2021

A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.

HR+ MBC: Prognostic Factors and Treatment Planning

October 11th 2021

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

Identifying PIK3CA Mutations in HR+ HER2- MBC

October 11th 2021

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.